irinotecan has been researched along with belinostat in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, DH; Hong, YS; Jang, SJ; Jung, KA; Kim, JC; Kim, SM; Kim, TW; Lee, JS; Moon, DH; Na, YS; Ryu, MH | 1 |
| Alharbi, SA; Chan, CEL; Chinnathambi, A; Goh, BC; Ho, PC; Lee, LS; Lee, SC; Lim, SW; Sethi, G; Soo, R; Wang, L; Wong, AL; Wong, FC; Yong, WP | 1 |
| Abbott, KL; Chandran, A; Chaudhury, CS; Dvorak, Z; Jiskrova, E; Mani, S; Pondugula, SR; Poulikova, K; Vishveshwara, S; Vyhlidalova, B | 1 |
| Steventon, G | 1 |
1 review(s) available for irinotecan and belinostat
| Article | Year |
|---|---|
Uridine diphosphate glucuronosyltransferase 1A1.
Topics: Alleles; Bilirubin; Genotype; Glucuronosyltransferase; Humans; Hydroxamic Acids; Hyperbilirubinemia; Irinotecan; Sulfonamides | 2020 |
3 other study(ies) available for irinotecan and belinostat
| Article | Year |
|---|---|
The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Female; HCT116 Cells; Histone Deacetylase Inhibitors; HT29 Cells; Humans; Hydroxamic Acids; Irinotecan; Mice; Mice, Nude; Prodrugs; Random Allocation; Sulfonamides; Topoisomerase I Inhibitors; Tumor Burden; Whole Body Imaging; Xenograft Model Antitumor Assays | 2011 |
Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chromatography, Liquid; Drug Interactions; Glucuronosyltransferase; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Mass Spectrometry; Microsomes, Liver; Sulfonamides | 2017 |
Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cytochrome P-450 CYP3A; Female; Gene Expression; Hepatocytes; Humans; Hydroxamic Acids; Irinotecan; Male; Middle Aged; Molecular Docking Simulation; Pregnane X Receptor; Receptors, Steroid; Rifampin; Sulfonamides; Young Adult | 2019 |